All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD-alum
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
In line with previous large-scale analysis of trials involving subcutaneous administration of Diamyd®, the reults, encompassing a total of 109 patients, showed a statistically significant effect in the predefined HLA (Human Leukocyte Antigen) subgroup of trial participants.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD-alum
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
The analysis while not reaching statistical significance, supports a positive effect of subcutaneous injections of Diamyd® on delaying the progression to type 1 diabetes in HLA-type DR3-DQ2 group while no benefit vs placebo is seen in individuals negative for HLA-type DR3-DQ2.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GAD-alum
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Diabetologia published results from a meta study that demonstrates a highly significant and clinically relevant effect of Diamyd Medical's lead drug candidate Diamyd® on preserving endogenous insulin production in genetically defined subgroups of type 1 diabetes.